Pasithea Therapeutics Corp.

NasdaqCM:KTTA Stock Report

Market Cap: US$3.3m

Pasithea Therapeutics Past Earnings Performance

Past criteria checks 0/6

Pasithea Therapeutics's earnings have been declining at an average annual rate of -53.8%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 100% per year.

Key information

-53.8%

Earnings growth rate

-40.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-100.0%
Return on equity-88.5%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21
We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06
Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Revenue & Expenses Breakdown

How Pasithea Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:KTTA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1679
30 Jun 240-1689
31 Mar 240-1689
31 Dec 230-1688
30 Sep 230-1596
30 Jun 230-1596
31 Mar 230-14104
31 Dec 220-12103
30 Sep 220-791
30 Jun 220-480
31 Mar 220-360
31 Dec 210-250
30 Sep 210-330

Quality Earnings: KTTA is currently unprofitable.

Growing Profit Margin: KTTA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KTTA is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.

Accelerating Growth: Unable to compare KTTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KTTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: KTTA has a negative Return on Equity (-88.46%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:20
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pasithea Therapeutics Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Constantine DavidesD. Boral Capital LLC.